Despite the proliferation of advanced wound-care products to treat diabetic foot ulcers (DFUs), ranging from negative-pressure wound therapy to moist wound dressings and antimicrobials to artificial skin and growth factors, there has been minimal impact on clinical outcomes, according to Ronald Hill, PhD, managing partner at MxBiodevices LLC. The company has already completed two human clinical trials of its injectable wound-repair scaffold that is injected just under the wound surface to provide a healing structure.
“DFU is a very difficult chronic disease to treat,” Hill says. “All of the competitive products are topical devices, so they are layered on top of the wound surface. But...